Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart Inc. (VXRT) is a clinical-stage biotechnology company pioneering oral tablet vaccines for infectious diseases. This page aggregates official announcements, financial disclosures, and scientific developments related to its recombinant vaccine platform and clinical pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, manufacturing updates, and peer-reviewed research findings – all essential for evaluating Vaxart's position in the competitive vaccine market.
Key content focuses on tablet vaccine efficacy data, FDA communications, intellectual property developments, and comparative analyses of mucosal immunization approaches. Bookmark this page to monitor Vaxart's progress in redefining vaccine administration through its temperature-stable oral delivery system.
A study led by Duke University, published in bioRxiv, indicates that Vaxart's (NASDAQ: VXRT) oral COVID-19 vaccine candidate can reduce the airborne transmission of the SARS-CoV-2 virus in an animal model. Results suggest Vaxart’s oral tablet vaccine outperforms traditional injected vaccines by lowering viral shedding. The preclinical trials showed that vaccinated hamsters exhibited faster viral clearance and caused fewer infections in unvaccinated counterparts. Vaxart has initiated a global Phase II clinical trial for this oral vaccine, which targets the SARS-CoV-2 spike protein.
Vaxart, Inc. (NASDAQ: VXRT) has commenced recruiting participants for its Phase II clinical trial of an oral COVID-19 vaccine. The trial aims to enroll 96 U.S. subjects, including both COVID-19 naïve and mRNA vaccinated individuals, with dosing expected to start later this month. Vaxart plans to expand the trial internationally, beginning with India later in the year. The Phase II program is crucial for evaluating the vaccine's effectiveness, especially against emerging variants, building on promising results from prior nonhuman primate studies.
Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of James F. Cummings, M.D., as Chief Medical Officer. Dr. Cummings, with extensive expertise in vaccine development, will oversee Vaxart's Phase II clinical trials for its oral COVID-19 vaccine. Vaxart aims to revolutionize vaccination with its oral tablet formulations, facilitating easier distribution and administration. The company focuses on various infectious diseases, including norovirus and flu, and is developing a broad portfolio of oral recombinant vaccines.
Vaxart (NASDAQ: VXRT) announced that senior scientist Susan Johnson, PhD, will present at ID Week 2021 (Sept 29 - Oct 3) and the 15th Vaccine Congress (Oct 4 - 6). Dr. Johnson's presentation, scheduled for Oct 5, focuses on Vaxart's COVID-19 oral vaccine candidate, highlighting its ability to induce immune responses. The ID Week conference is a collaboration among leading infectious disease organizations, while the Vaccine Congress will gather experts to discuss advancements in vaccine research.
Vaxart, Inc. (NASDAQ: VXRT) announced the formation of a Manufacturing and Quality Advisory Board, aimed at enhancing its vaccine development efforts. The board, convened on August 21, comprises six experts with extensive experience in bioprocess development, regulatory affairs, and quality assurance. CEO Andrei Floroiu expressed excitement about leveraging their insights as Vaxart progresses toward late-stage development and commercialization of its oral vaccine portfolio, which includes candidates for COVID-19 and other viral diseases.
Vaxart, Inc. (NASDAQ: VXRT) announced that CEO Andrei Floroiu and CSO Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:40 a.m. ET. The presentation can be viewed here and on Vaxart's website. Vaxart is advancing its oral tablet COVID-19 vaccine into phase II trials, being the only oral COVID-19 vaccine supported by clinical data. The company develops a variety of oral recombinant vaccines and holds multiple patents for its innovative technology.
Vaxart, Inc. (Nasdaq: VXRT) announced that CEO Andrei Floroiu and CSO Dr. Sean Tucker will present at the H.C. Wainwright 23rd Annual Global Investor Conference from Sept. 13-15, 2021. The presentation will be available on demand starting at 7:00 a.m. ET on Sept. 13. Vaxart's oral tablet COVID-19 vaccine, which has completed phase I trials, is set to enter phase II trials this year, being the only oral vaccine backed by clinical data. Vaxart develops a range of oral vaccines targeting various diseases, supported by its proprietary delivery platform.
Vaxart, Inc. (NASDAQ: VXRT) announced that Dr. Julie M. Cherrington has joined its board of directors. Dr. Cherrington, an accomplished life science executive, brings extensive experience in drug development and commercialization. Her leadership background includes roles as CEO in multiple biotech firms and significant contributions to several FDA-approved products. Vaxart is advancing oral vaccines for COVID-19 and norovirus, positioning itself for transformative impacts in public health. The board expressed optimism regarding Dr. Cherrington's insights as Vaxart progresses in its clinical trials.
Vaxart, Inc. (NASDAQ: VXRT) announced the establishment of a Scientific and Clinical Advisory Board on August 19, 2021. The board includes eight experts in immunology and infectious diseases, with its first meeting held on July 24, 2021. CEO Andrei Floroiu highlighted the board's significance for advancing Vaxart's oral vaccine programs. Members include renowned figures such as Dr. Robert Belshe and Dr. Ralph Baric, who bring extensive experience in vaccine development and research. Vaxart aims to leverage this expertise to enhance public health through its innovative oral vaccine delivery platform.
On August 5, 2021, Vaxart, Inc. (Nasdaq: VXRT) released its second-quarter business update, showcasing progress in oral tablet vaccines. The company raised $36.2 million from its $250 million at-the-market facility and signed a licensing agreement with Altesa Biosciences for its antiviral, Vapendavir, potentially generating $130 million in milestone payments. Financially, Vaxart reported a revenue decrease to $112,000 and a net loss of $16.1 million, compared to $523,000 and $9.0 million in the prior year’s quarter. Research initiatives continue for COVID-19 and norovirus vaccines.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
